Sobi Presents Long-Term Altuvoct Data, Reinforcing Haemophilia A Treatment Position

Event summary

  • Sobi will present seven scientific abstracts at the EAHAD 2026 Congress, including an oral presentation on three years of Altuvoct (efanesoctocog alfa) treatment.
  • The XTEND-ed study data confirms Altuvoct’s protection for haemophilia A patients, mirroring initial registration data with no unexpected safety concerns.
  • Sobi and Sanofi collaborate on Altuvoct’s development and commercialization, with Sobi holding final rights in Europe, North Africa, Russia, and the Middle East.
  • ALTUVOCT is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A, applicable to all age groups and disease severities.

The big picture

Sobi's presentation at EAHAD 2026 underscores the ongoing focus on long-term data validation for specialized therapies in rare disease areas. The collaboration with Sanofi remains crucial for global commercialization, particularly as competition in the haemophilia market intensifies. The continued positive data for Altuvoct reinforces Sobi’s strategic focus on rare blood disorders, a market segment with significant unmet needs and premium pricing potential.

What we're watching

Market Adoption
The long-term data release will likely influence physician prescribing habits and patient access, impacting Altuvoct’s market share within the competitive haemophilia A treatment landscape.
Collaboration Dynamics
Continued success of Altuvoct hinges on the ongoing partnership with Sanofi; any shifts in commercialization strategies or regional responsibilities could impact revenue distribution and market reach.
Clinical Expansion
The presentation of data from the FREEDOM study and CHESS III study suggests Sobi is exploring broader applications and real-world effectiveness of its haemophilia treatments, which could expand its addressable market.